Latest News
Good Viruses, bad bacteria
The partnership will focus on a novel drug delivery for bacteriophages to fight infections.
Drug Delivery Platform Could Usher Phage Therapeutics to the Clinichip
A biotech startup aims to revolutionize the use of phage therapeutics with a drug delivery platform enabling them to be used in real-world clinical settings. Paldara was founded after its young creator and CEO William Colton won his first pitch competition at Oklahoma State University (OSU) based on his studies using bacteriophages to combat antibiotic-resistant bacteria.
INDUSTRY MATTERS WITH WILLIAM COLTON: Fighting Antibiotic Resistance with Bacteriophage Therapy and Novel Hydrogel Delivery
William Colton’s Paldara Pharmaceuticals harnesses bacteriophages for antibiotic resistance, using a hydrogel delivery system to improve therapy effectiveness.
Oklahoma State University graduate invents breakthrough treatment for ‘Superbugs
A 26-year-old researcher collaborating with Oklahoma State University is on the cusp of launching biomedical technology that could revolutionize the way we fight incurable bacterial infections that claim thousands of lives around the world every year.
OSU grad’s breakthrough could save lives from deadly superbugs
STILLWATER, Okla. (AP) — A 26-year-old Oklahoma State University graduate has developed a breakthrough technology that could revolutionize the fight against antibiotic-resistant bacteria, also known as superbugs, which kill more than 35,000 Americans each year.
Paldara, Mayo Clinic Push Phage Therapy Toward First Human Trials
September 23, 2025 | Phage therapy, a treatment that uses viruses to fight bacterial infections, may finally be heading toward mainstream clinical practice. Paldara, a biotech startup, is developing a delivery platform that promises to stabilize and sustain bacteriophages and make phage therapy accessible for patients.